Claims for Patent: 6,166,046

Summary for Patent: 6,166,046

Title:	Combination of atovaquone with proguanil for the treatment of protozoal infections
Abstract:	The invention relates to combinations of atovaquone and proguanil, their use in the treatment and prophylaxis of parasitic infections such as protozoal parasitic infections, e.g., malaria and toxoplasmosis, and infections caused by P. carinii and their use in the manufacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.
Inventor(s):	Gutteridge; Winston Edward (Beckenham, GB), Hutchinson; David Brian Ashton (Beckenham, GB), Latter; Victoria Susan (Beckenham, GB), Pudney; Mary (Beckenham, GB)
Assignee:	Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:	09/409,871
Patent Claims:	1. A combinations of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone and 1-(4-chlorophenyl)-5-isopropylbiguianide hydrochloride wherein the 2-[-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone and the 1-(4-chlorophenyl)-5-isopropylbiguanide hydrochloride are present in a ratio in the range of 1:1 to 3:1. 2. A combination of 2-8 4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone and 1-(4-chlorophenyl-5-isopropylbiguanide hydrochloride wherein the ratio of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone to 1-(4-chlorophenyl-5-isopropylbiguanide hydrochloride if 5:2. 3. A combination according to claim 1 or claim 2 wherein the 2-[4(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone is in the form of the trans isomer or a mixture of the cis and trans isomers in which the trans isomer predominates. 4. A pharmaceutical formulation comprising a combination according to claim 1 or claim 2 in association with one or pharmaceutically acceptable carriers thereof. 5. A unit dose formulation comprising 50 mg to 3 mg each of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone and 1-(4-chlorophenyl)-5-isopropylbiguanide hydrochloride in a ratio in the range of 1:1 to 3:1. 6. A unit dose formulation according to claim 5 comprising 500 mg of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone and 200 mg of 1-(4-chlorophenyl)-5-isopropylbiguianide hydrochloride.